leadf
logo-loader
OTCQB:BIOAF TSX-V:BTI

Bioasis Technologies Inc.

Receive alerts
Market:
OTCQB
Market Cap:
$18.78 m
Price
0.28 USD
Change
-6.97%
52 weeks high
0.38
52 weeks low
0.09

In brief

Bioasis Technologies Inc. is a biopharmaceutical company developing the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The delivery of therapeutics across the blood brain barrier represents the final frontier in treating neurological disorders. The in-house development programs at Bioasis are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.

Insight Widest with the analysis, Proactive gives perspectives that others don't.

Bioasis on a roll after Chiesi validates the power of its technology to propel drugs across the blood-brain barrier

Bioasis will get an upfront payment of $3 million from Chiesi and may also be eligible to receive additional development milestone payments of up to $138 million

2 weeks, 1 day ago